GLUCORAGE ® (Metformin Hcl Tablets & combinations)
1.jpg)
First-line agent to treat type 2 diabetes mellitus ,Antihyperglycemic drugs used to treat type 2 diabetes.
GLUCORAGE ® (Metformin Hcl Tablets & combinations) is an oral antidiabetic drug in the biguanide class. It is the first-line drug of choice for the treatment
of type 2 diabetes, in particular, in overweight and obese people and those with normal kidney function. Its use in gestational diabetes has been limited by
safety concerns although at least one study has been conducted which showed no concerns for children prenatally exposed to Metformin up to 2 years of age.
It is also used in the treatment of polycystic ovary syndrome, and has been investigated for other diseases where insulin resistance may be an
important factor. Metformin works by suppressing glucose production from three-carbon molecules
(like propionic acid, a by product of dietary fibre fermentation in the large intestine and pyruvate, a by product of glucose breakdown in the muscles) by the liver.
GLUCORAGE ® (Metformin Hcl Tablets & combinations) is primarily used for type 2 diabetes, but is increasingly being used
in polycystic ovary syndrome (PCOS),[14] and in prediabetes.
Type 2 diabetes
The American Diabetes Association recommends metformin as a first-line agent to treat type 2 diabetes mellitus.
COMBINATIONS AVAILABLE FOR: Type 2 Diabetes
Linagliptin/metformin hydrochloride) Tablets
2.5 mg linagliptin/500 mg metformin HCl
Metformin hydrochloride and Glibenclamide
Vildagliptin/Metformin hydrochloride
Glyburide and Metformin hydrochloride
tablets, USP
Metformin Hydrochloride and Voglibose Tablets
METFORMIN HYDROCHLORIDE EXTENDED-RELEASE
Benfotiamine and metformin HCl tablets.
GLUCORAGE ® is a registered trademark of Taj Pharma A/S.
US Patent No. 56,663,21
Manufactured for: TAJ PHARMA LIMITED A/S
DK-6755 Bagsvaerd, Denmark
For information contact: Taj Pharma Inc. 332 College RoadWest
Princeton, New Jersey 08540
or www.tajpharma.com
© 2008–2014 TAJ GROUP., INDIA
432WSSWE 332-1 April 2012
22.jpg)
%2B-rr.jpg)
%2Bee.jpg)
-ew.jpg)
-wall.jpg)
-we.jpg)
.jpg)
First-line agent to treat type 2 diabetes mellitus ,Antihyperglycemic drugs used to treat type 2 diabetes.
GLUCORAGE ® (Metformin Hcl Tablets & combinations) is an oral antidiabetic drug in the biguanide class. It is the first-line drug of choice for the treatment
of type 2 diabetes, in particular, in overweight and obese people and those with normal kidney function. Its use in gestational diabetes has been limited by
safety concerns although at least one study has been conducted which showed no concerns for children prenatally exposed to Metformin up to 2 years of age.
It is also used in the treatment of polycystic ovary syndrome, and has been investigated for other diseases where insulin resistance may be an
important factor. Metformin works by suppressing glucose production from three-carbon molecules
(like propionic acid, a by product of dietary fibre fermentation in the large intestine and pyruvate, a by product of glucose breakdown in the muscles) by the liver.
GLUCORAGE ® (Metformin Hcl Tablets & combinations) is primarily used for type 2 diabetes, but is increasingly being used
in polycystic ovary syndrome (PCOS),[14] and in prediabetes.
Type 2 diabetes
The American Diabetes Association recommends metformin as a first-line agent to treat type 2 diabetes mellitus.
COMBINATIONS AVAILABLE FOR: Type 2 Diabetes
Linagliptin/metformin hydrochloride) Tablets
2.5 mg linagliptin/500 mg metformin HCl
Metformin hydrochloride and Glibenclamide
Vildagliptin/Metformin hydrochloride
Glyburide and Metformin hydrochloride
tablets, USP
Metformin Hydrochloride and Voglibose Tablets
METFORMIN HYDROCHLORIDE EXTENDED-RELEASE
Benfotiamine and metformin HCl tablets.
GLUCORAGE ® is a registered trademark of Taj Pharma A/S.
US Patent No. 56,663,21
Manufactured for: TAJ PHARMA LIMITED A/S
DK-6755 Bagsvaerd, Denmark
For information contact: Taj Pharma Inc. 332 College RoadWest
Princeton, New Jersey 08540
or www.tajpharma.com
© 2008–2014 TAJ GROUP., INDIA
432WSSWE 332-1 April 2012
No comments:
Post a Comment